Chandra Bhagat Pharma Ltd vs Fabino Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Chandra Bhagat Pharma Ltd is ₹ 43.9 as of 10 Jun 15:30 . The P/E Ratio of Chandra Bhagat Pharma Ltd is 0 as of March 2023 .The P/E Ratio of Fabino Enterprises Ltd is 600 as of March 2023 . The Market Cap of Chandra Bhagat Pharma Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Fabino Enterprises Ltd is ₹ 6.3 crore as of March 2023 . The Dividend Payout of Chandra Bhagat Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Fabino Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Chandra Bhagat Pharma Ltd

Chandra Bhagat Pharma Limited was incorporated as a Private Limited Company with the name 'Chandra Bhagat Pharma Private Limited' at Mumbai on March 10, 2003.
Consequent upon the conversion of the Company from Private Limited Company to Public Limited Company, the name of the Company was changed to 'Chandra Bhagat Pharma Limited' on March 20, 2019. The Company incorporated in March, 2003 by Mr. Hemant Bhagat and Late.
Shree Chandravadan Bhagat.
On April 1, 2003, the Company acquired the going concern business of M/s.
Chandra Bhagat Corporation, partnership firm along with all its assets and liabilities.

About Fabino Enterprises Ltd

Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain.
The Company was incorporated as 'Fabino Life Sciences Private Limited' on October 27, 2011 with the Registrar of Companies, Delhi and Haryana.
Subsequently, the Company got converted to Public Limited Company and the name of Company was changed to 'Fabino Life Sciences Limited'.
A fresh Certificate of Incorporation was issued on March 21, 2015 by the Registrar of Companies, Delhi. The Company operate in the business of manufacturing, marketing of pharmaceutical, allopathic, herbal, veterinary, and other consumer products like, packing, trading, etc.
The core business is marketing of pharmaceutical formulation & products in domestic market through its own distribution network and sales force under own brand name, getting Ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

FAQs for the comparison of Chandra Bhagat Pharma Ltd and Fabino Enterprises Ltd

Which company has a larger market capitalization, Chandra Bhagat Pharma Ltd or Fabino Enterprises Ltd?

Market cap of Chandra Bhagat Pharma Ltd is 33 Cr while Market cap of Fabino Enterprises Ltd is 4 Cr

What are the key factors driving the stock performance of Chandra Bhagat Pharma Ltd and Fabino Enterprises Ltd?

The stock performance of Chandra Bhagat Pharma Ltd and Fabino Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chandra Bhagat Pharma Ltd and Fabino Enterprises Ltd?

As of June 15, 2026, the Chandra Bhagat Pharma Ltd stock price is INR ₹43.9. On the other hand, Fabino Enterprises Ltd stock price is INR ₹20.31.

How do dividend payouts of Chandra Bhagat Pharma Ltd and Fabino Enterprises Ltd compare?

To compare the dividend payouts of Chandra Bhagat Pharma Ltd and Fabino Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.